Loading...
•
Dec 31, 2024
Aytu BioScience Q2 2025 Earnings Report
Aytu BioPharma reported its fiscal 2025 second quarter operational and financial results, showing a net income of $0.8 million and adjusted EBITDA of $1.3 million.
Key Takeaways
Aytu BioPharma reported a net income of $0.8 million and adjusted EBITDA of $1.3 million for the second quarter of fiscal 2025. The company saw an 86% sequential increase in Pediatric Portfolio net revenue and a 16% sequential increase in ADHD Portfolio net revenue, marking the first quarterly sequential prescription increase for both portfolios since Q2 fiscal 2023.
Net income for Q2 fiscal 2025 was $0.8 million, or $0.13 net income per share basic.
Adjusted EBITDA for Q2 fiscal 2025 was $1.3 million.
Pediatric Portfolio net revenue increased 86% sequentially to $2.4 million.
ADHD Portfolio net revenue increased 16% sequentially to $13.8 million.
Aytu BioScience
Aytu BioScience
Aytu BioScience Revenue by Segment
Revenue by Segment
ADHD Portfolio Revenue
CapyFin.comPediatric Portfolio Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Aytu BioPharma expects continued revenue and adjusted EBITDA growth, driven by strategic realignments, operational efficiencies, and potential in-licensed or acquired products. The company aims to generate positive cash flows and increase stockholder value.
Positive Outlook
- Expects to realize at least $2.0 million in annual cost savings from corporate optimization initiatives.
- Aims to generate positive cash flows and increase stockholder value.
- Focused on commercializing novel prescription therapeutics and leveraging its streamlined organization.
- Seeking opportunities to leverage commercial infrastructure and Aytu RxConnect platform.
- Pursuing additional in-licensed or acquired products to drive future growth.
Challenges Ahead
- The company's ADHD inventory has a higher cost due to allocation of overhead costs from the Grand Prairie, Texas manufacturing facility to reduced production, which is expected to normalize in coming quarters.
- Gross profit percentage decreased to 66% from 78% in the prior year, primarily due to increased cost of sales in ADHD inventory.
- Net income per share diluted was a loss of $0.26, compared to a loss of $0.04 in the prior year.
- Adjusted EBITDA decreased to $1.3 million from $5.5 million in the prior year period.
- The company's fiscal 2025 second quarter results were impacted by a $3.0 million derivative warrant liabilities gain, which contrasts with a $0.6 million loss in the prior year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income